Aktieanalys

Alzecure: Additional phase IIa data from ACD440 neuropathic pain study - Redeye

{newsItem.title}

Redeye Publicerad: 21 Sep 2023 07:40

AlzeCure Pharma

Redeye comments on the additional data presented from the phase IIa study with ACD440 in neuropathic pain and reiterate our positive stance to the outcome.

Länk till analysen i sin helhet: https://www.redeye.se/research/943572/alzecure-additional-phase-iia-data-from-acd440-neuropathic-pain-study?utm_source=finwire&utm_medium=RSS

Nyheter om AlzeCure Pharma

Läses av andra just nu

Om aktien AlzeCure Pharma

Senaste nytt